News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Profectus BioSciences, Inc. Receives $5.4M Grant to Develop a Monocolonal Antibody Against Infection by Nipah/Hendra Viruses


12/13/2011 2:02:37 PM

BALTIMORE--(BUSINESS WIRE)--Profectus BioSciences, Inc. (Profectus), a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced today it has received a grant under the Partnerships for Biodefense RFA by the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH. This $5.4M award supports the preclinical development of m102.4, an antibody intended as a post-exposure prophylactic against Nipah or Hendra virus infection.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES